NetworkNewsBreaks – Zenosense, Inc. (ZENO) Poise
Post# of 53
(Total Views: 152)
Posted On: 07/03/2018 6:52:59 PM
NetworkNewsBreaks – Zenosense, Inc. (ZENO) Poised to Capitalize on Fast-growing Market
Healthcare technology company Zenosense (OTC: ZENO), through its joint venture ownership of MIDS Medical Limited (“MML”), is developing “MIDS”, a nano-magnetic detection technology to allow true laboratory accuracy at the point-of-care (“POC”). A recent article discussing the company reads: “Zenosense, through MML, intends to develop wider applications of its MIDS technology platform to include POC immunoassay testing of many other medical conditions and diseases. MML’s test results on its Hybrid Strip development system already indicate that MML can detect commercially available assay beads at extremely low levels. The successful incorporation of magnetic detection should provide a significant improvement in accuracy over existing POC devices that are limited to imperfect optical detection, which cannot equal laboratory analyzer performance. … The system uniquely positions Zenosense to capitalize on a fast-growing market. According to Grand View Research, the global cardiac biomarkers market is expected to reach $13.3 billion by 2024, and Markets and Markets report that the global immunoassay testing market is projected to be worth $25.45 billion by 2021.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Healthcare technology company Zenosense (OTC: ZENO), through its joint venture ownership of MIDS Medical Limited (“MML”), is developing “MIDS”, a nano-magnetic detection technology to allow true laboratory accuracy at the point-of-care (“POC”). A recent article discussing the company reads: “Zenosense, through MML, intends to develop wider applications of its MIDS technology platform to include POC immunoassay testing of many other medical conditions and diseases. MML’s test results on its Hybrid Strip development system already indicate that MML can detect commercially available assay beads at extremely low levels. The successful incorporation of magnetic detection should provide a significant improvement in accuracy over existing POC devices that are limited to imperfect optical detection, which cannot equal laboratory analyzer performance. … The system uniquely positions Zenosense to capitalize on a fast-growing market. According to Grand View Research, the global cardiac biomarkers market is expected to reach $13.3 billion by 2024, and Markets and Markets report that the global immunoassay testing market is projected to be worth $25.45 billion by 2021.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)